Goldman Sachs Group Inc. Sells 55,382 Shares of Establishment Labs Holdings Inc. $ESTA

Key Points

• Goldman Sachs Group Inc. decreased its stake in Establishment Labs Holdings Inc. by 39.6%, selling 55,382 shares and retaining 84,468 shares worth approximately $3.45 million as of the latest SEC filing.
• Establishment Labs reported a quarterly loss of $0.57 per share, falling short of analysts' expectations, but its revenue increased 16.1% year-over-year, reaching $51.30 million.
• Wall Street analysts maintain a consensus rating of "Moderate Buy" for Establishment Labs, with an average price target of $56.50, indicating a positive outlook despite a recent downgrade from Needham & Company LLC.

Goldman Sachs Group Inc. reduced its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 39.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 84,468 shares of the company's stock after selling 55,382 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.29% of Establishment Labs worth $3,447,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd bought a new position in shares of Establishment Labs during the first quarter valued at $81,000. Elevation Point Wealth Partners LLC bought a new position in shares of Establishment Labs during the first quarter valued at $207,000. Patriot Financial Group Insurance Agency LLC bought a new position in shares of Establishment Labs during the first quarter valued at $234,000. ADAR1 Capital Management LLC bought a new position in shares of Establishment Labs during the first quarter valued at $326,000. Finally, New York State Common Retirement Fund bought a new position in shares of Establishment Labs during the first quarter valued at $894,000. 72.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on ESTA shares. Needham & Company LLC reissued a "buy" rating and set a $48.00 price objective on shares of Establishment Labs in a report on Friday, June 13th. Mizuho raised their target price on Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Wall Street Zen raised Establishment Labs from a "sell" rating to a "hold" rating in a report on Saturday. Citigroup lifted their price target on Establishment Labs from $38.00 to $47.00 and gave the company a "neutral" rating in a report on Wednesday, July 9th. Finally, Canaccord Genuity Group initiated coverage on Establishment Labs in a report on Wednesday, August 20th. They issued a "buy" rating and a $60.00 price target for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $56.50.

Establishment Labs Stock Down 2.7%

Shares of ESTA traded down $1.09 on Friday, hitting $39.46. The company's stock had a trading volume of 158,628 shares, compared to its average volume of 236,551. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 9.71. The firm's fifty day moving average price is $40.24 and its 200-day moving average price is $37.86. Establishment Labs Holdings Inc. has a fifty-two week low of $26.56 and a fifty-two week high of $50.85. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -12.94 and a beta of 0.85.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.03). Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The business had revenue of $51.30 million during the quarter, compared to analyst estimates of $50.80 million. During the same quarter in the prior year, the firm posted ($0.62) earnings per share. Establishment Labs's revenue for the quarter was up 16.1% compared to the same quarter last year. Establishment Labs has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.